deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03037385

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)

A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Sponsor: Hoffmann-La Roche

Conditions Adenocarcinoma Adenocarcinoma, Papillary Bronchial Neoplasms Carcinoma Carcinoma, Bronchogenic Carcinoma, Neuroendocrine Carcinoma, Non-Small-Cell Lung Colonic Diseases Colonic Neoplasms Colorectal Neoplasms Digestive System Disease Digestive System Neoplasm Endocrine Gland Neoplasm Endocrine System Diseases Gastrointestinal Disease Gastrointestinal Neoplasms Head and Neck Neoplasms Intestinal Disease Intestinal Neoplasms Lung Diseases Lung Neoplasm Medullary Thyroid Cancer Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neuroectodermal Tumors Neuroendocrine Tumors RET-altered Colon Cancer RET-altered Non Small Cell Lung Cancer RET-altered Papillary Thyroid Cancer RET-altered Solid Tumors Respiratory Tract Disease Respiratory Tract Neoplasms Thoracic Neoplasms Thyroid Cancer, Papillary Thyroid Diseases Thyroid Neoplasm
Interventions pralsetinib (BLU-667)
Updated 47 times since 2017 Last updated: May 30, 2025 Started: Mar 17, 2017 Primary completion: Mar 21, 2024 Completion: Mar 21, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03037385, this PHASE1/PHASE2 trial focuses on Adenocarcinoma and Adenocarcinoma, Papillary and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 47 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~May 2018 · 3 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Dec 2019 · 3 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Mar 2023 · 3 months · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Aug 2023 · 3 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Mar 2024 · 3 months · monthly snapshot~Mar 2024 – ~May 2024 · 2 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

47 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jun 2025 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Sep 2024 — Jun 2025 [monthly]

    Completed PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. May 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 42 earlier versions

  1. Mar 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Dec 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Sep 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Aug 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. May 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Apr 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Mar 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Dec 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Nov 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  10. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  11. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  12. Jun 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  13. Apr 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  14. Mar 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  15. Jan 2022 — Mar 2022 [monthly]

    Recruiting PHASE1_PHASE2

  16. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE1_PHASE2

  17. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE1_PHASE2

  18. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE1_PHASE2

  19. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1_PHASE2

  20. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  21. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE1_PHASE2

  22. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  23. Jun 2020 — Sep 2020 [monthly]

    Recruiting PHASE1_PHASE2

  24. Mar 2020 — Jun 2020 [monthly]

    Recruiting PHASE1_PHASE2

  25. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  26. Dec 2019 — Feb 2020 [monthly]

    Recruiting PHASE1_PHASE2

  27. Sep 2019 — Dec 2019 [monthly]

    Recruiting PHASE1_PHASE2

    Phase: PHASE1 → PHASE1_PHASE2

  28. Jun 2019 — Sep 2019 [monthly]

    Recruiting PHASE1

  29. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE1

  30. Feb 2019 — Apr 2019 [monthly]

    Recruiting PHASE1

  31. Dec 2018 — Feb 2019 [monthly]

    Recruiting PHASE1

  32. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

  33. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  34. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  35. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  36. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  37. Feb 2018 — May 2018 [monthly]

    Recruiting PHASE1

  38. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE1

  39. Sep 2017 — Dec 2017 [monthly]

    Recruiting PHASE1

  40. Jun 2017 — Sep 2017 [monthly]

    Recruiting PHASE1

  41. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  42. Feb 2017 — May 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Amsterdam, Netherlands , Ann Arbor, United States , Aurora, United States , Austin, United States , Barcelona, Spain , Beijing, China , Berlin, Germany , Bordeaux, France , Boston, United States and 49 more locations